Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Graft-versus-host disease prophylaxis with abatacept plus intermediate dose cyclophosphamide for GVHD prophylaxis after peripheral blood stem transplantation: a single institution study.
Journal: Bone marrow transplantation
Published: May 21, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Journal: Lancet (London, England)
Published: April 29, 2026
Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.
Journal: Haematologica
Published: January 13, 2026
Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.
Journal: Haematologica
Published: December 23, 2024
Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.
Journal: JMIR cancer
Published: October 28, 2024
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratification.
Journal: Blood cancer journal
Published: October 17, 2024
Efficacy of hedgehog pathway inhibitors as adjuvant in treating steroid-refractory sclerodermatous chronic graft-versus-host disease.
Journal: Journal of the American Academy of Dermatology
Published: August 14, 2024
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Journal: American journal of hematology
Published: July 15, 2020
Last Updated: 09/26/2026